sitefansalaran International News

Swiss companies Roche (ROG.S), opens new tab and Novartis on Friday flagged they did not expect to be hit by President Donald Trump's latest pharmaceutical tariff announcement because they are in the process of building new U.S. sites and investing there. Trump said on Thursday the United States will impose a 100% tariff on imports of branded or patented pharmaceutical products from October 1, unless a given pharmaceutical company is building a manufacturing plant in the U.S. Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here. A Roche spokesperson pointed to an August 25 announcement that its Genentech unit had broken ground for a facility in Holly Springs, North Carolina, as well as its $50 billion pledge to invest in U.S. manufacturing and research and development. Roche and Novartis (NOVN.S), opens new tab are Switzerland's two biggest pharmaceutical firms with major U.S. production operations. Novartis, which made a $23 billion U.S. investment pledge earlier this year, said that Trump's 100% tariff announcement should not have an impact on the company. "We have ongoing construction and expect to announce five new sites to be under construction before end of year," Novartis said. Investors appeared to shrug off...

South Korea's drug watchdog said on Tuesday it would seek information from relevant companies after U.S. President Donald Trump linked the use of Tylenol by pregnant women to autism, a claim that is unsupported by scientific evidence. The drug regulator said it would review the opinions and documents provided by the companies. On Monday, Trump also linked autism to childhood vaccine use. "Since the U.S. government’s announcement contained little substance, we have no additional comments," South Korea's food and drug safety ministry said on Wednesday. "However, we plan to request relevant papers and data from paracetamol importers and manufacturers." After Trump linked paracetamol to autism, international health agencies reaffirmed it was safe to use during pregnancy. The World Health Organization said there was no conclusive scientific evidence linking paracetamol use during pregnancy to autism. The European Medicines Agency said available evidence had found no such link and advised use of the lowest effective doses of the drug according to the frequency needed.

World Pharmacists Day is a global healthcare event celebrated on September 25th every year since 2009. It commemorates the anniversary of the International Pharmaceutical Federation, which was established in 1912 to recognize the vital role of pharmacists in healthcare systems around the globe. This day promotes awareness of pharmacist contributions to ensure the medication safety, improve the health and, most importantly, providing patient care. Significance of World Pharmacists Day Pharmacist Day recognizes, celebrates, and honours pharmacists' vital role in healthcare. This day provides an excellent opportunity to express gratitude to those on the front lines of pharmacy, demonstrating patience and compassion. We appreciate their commitment, ability to deal with difficult patients, skill in deciphering doctors' handwriting, and constant smiles, even when working extra hours. Pharmacist Day also celebrates the growth of the pharmacy profession in India and provides a platform for communication between pharmacists from different sectors and backgrounds, offering professional insights in the field of pharmacy. World Pharmacists Day 2025 Theme This year, 2025, the World Pharmacist Day Theme is “Think Health, Think Pharmacist”. This theme highlights the vital role of pharmacists as key healthcare providers beyond just dispensing medicines. It emphasizes their contribution to patient care and health systems. The campaign urges full...

European Union and British health agencies confirmed the safety of paracetamol during pregnancy, disputing a warning from U.S. President Donald Trump linking the popular pain medication to autism. The World Health Organization said on Tuesday that evidence of a link remained inconsistent and urged caution in drawing conclusions. Trump had on Monday linked autism to childhood vaccine use and the taking of Tylenol by women when pregnant, elevating claims not backed by scientific evidence to the forefront of U.S. health policy. The European Medicines Agency said on Tuesday that there was no new evidence that would require changes to the region’s current recommendations for the use of paracetamol, known as Tylenol in the United States, during pregnancy. “Available evidence has found no link between the use of paracetamol during pregnancy and autism,” the EMA said in a statement, adding paracetamol could be used during pregnancy when needed, though at the lowest effective dose and frequency. On Monday, Britain’s health regulator said that it was safe to use. “The evidence remains inconsistent,” WHO spokesperson Tarik Jašarević told a Geneva press briefing when asked about a possible link between paracetamol use in pregnancy and autism. He cited unspecified studies that pointed to a possible link but said...

Sanofi and Regeneron’s Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion •Recommendation for adults and adolescents based on phase 3 studies showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo •If approved, Dupixent would be the first targeted medicine in over a decade indicated for CSU in the EU Paris and Tarrytown, September 22, 2025. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Dupixent (dupilumab) in the EU for the treatment of chronic spontaneous urticaria (CSU) in adults and adolescents. This recommendation covers those aged 12 years and above with moderate to severe disease, with inadequate response to histamine-1 antihistamines (H1AH), and who are naive to anti-immunoglobulin E (IgE) therapy. A final decision is expected in the coming months. The positive CHMP opinion is supported by data from two studies in the LIBERTY-CUPID phase 3 program (NCT04180488; Study A and Study C), both of which demonstrated Dupixent significantly reduced itch and hives at 24 weeks compared to placebo. A third study from the LIBERTY-CUPID program, Study B, conducted in a different CSU patient population, provided additional safety data. The safety results of...

Seven northeastern U.S. states, including New York, Pennsylvania, New Jersey, Connecticut, Massachusetts, Maine, and Rhode Island, have formed the Northeast Public Health Collaborative to provide independent vaccination guidance and counter new federal restrictions on vaccine access. Critics of the federal limits have accused Health and Human Services Secretary Robert F. Kennedy of promoting vaccine hesitancy. The alliance has recommended COVID-19 vaccines for children as young as six months, adolescents, adults at higher risk, and all adults—contrary to the more restrictive federal guidelines. Governors have also granted pharmacists the authority to administer vaccines more broadly, even in areas where the federal government has limited access.

Most recently, the Phase III pivotal clinical trial results of Fazamorexant, a first-class innovative anti-insomnia drug independently developed by Yangtze River Pharmaceutical Group,were globally unveiled for the first time at the World Sleep Congress 2025 combined with the annual meeting of the Asian Society of Sleep Medicine (ASSM 2025). The announcement has garnered widespread attention within the international sleep medicine community. This groundbreaking achievement marks a significant milestone in the global development of innovative treatments for sleep disorders. The World Sleep Congress, held in Singapore this year, is the highest-level academic event in the field of sleep medicine gathering top international experts and scholars. The release of the trial results of Fazamorexant marks an important breakthrough made by China in original new drugs, with increasing influence in the global academic stage. At the “Orexin/Hypocretin System: Clinical Use”, a special session co-chaired by Professor Han Fang, former Secretary-General of the World Association of Sleep Medicine and former President of the ASSM from Peking University People’s Hospital, and Professor Seung-Chul Hong, President of the Korean Society of Sleep Research, a study report was given by Dr. Zhu Wenjun, a postdoctoral fellow at Peking University People’s Hospital, providing a detailed interpretation of the Phase III...

An artificial joint is a prosthesis or prosthetic joint, made of plastic, ceramic or metal, which is implanted to replace a damaged or diseased natural joint. The surgical procedure for implanting an artificial joint involves removal of the damaged or diseased joint of knee, hip, shoulder, and other joints. After removal of damaged part, surgeon replaces it with the prosthetic joint. The artificial joint mimics the natural movement of the original joint, allowing for improved mobility and pain reduction. Allied Market Research published a report, titled, ”Artificial Joints Market by Type (Cemented Artificial Joints and Non-cemented Artificial Joints), Application (Artificial Knee Joints, Artificial Hip Joints, and Others), Material (Ceramics, Alloy, and Others), and End User (Hospitals and Others): Global Opportunity Analysis and Industry Forecast, 2023-2032.” According to the report, the global artificial Joints industry was valued at USD 20.2 billion in 2022 and is projected to reach USD 31.8 billion by 2032, registering a CAGR of 4.6% from 2023 to 2032. The report provides a detailed analysis of the top investment pockets, top winning strategies, drivers & opportunities, market size & estimations, competitive landscape, and evolving market trends. The market study is a helpful source of information for the frontrunners, new...

The United States will prioritize frontline health supplies, staff, and working directly with countries under a new global health strategy released by the Trump administration on Thursday after months of uncertainty following sweeping aid cuts. The plan also requires recipient countries to co-invest in global health goals around diseases such as HIV/AIDS, malaria, tuberculosis and polio, and outlines plans to transition away from aid to self-reliance over the next few years. The strategy, named "America First Global Health Strategy", also covers the U.S. response to pandemic threats and outbreaks, but does not mention a host of areas that have been prioritized under past administrations, including maternal and child health, cholera, and vaccine-preventable diseases such as measles. "We must keep what is good about our health foreign assistance programs while rapidly fixing what is broken," Secretary of State Marco Rubio wrote in the introduction to the strategy. STRATEGY COMES AFTER TRUMP'S DISMANTLING OF USAID The strategy is the clearest sign yet on what the U.S., previously the world's biggest global health funder, now aims to prioritize, although it provided no budget details. It follows the dismantling of the United States Agency for International Development earlier this year, which has been brought into the State Department as...

Apple Watch Series 11 models that go on sale on Friday can notify users that they may have high blood pressure, in a feature the company has powered using artificial intelligence rather than a blood pressure monitor. The notification feature, which will work with models back to the Apple Watch Series 9, came about from applying AI models to existing sensor data, said Sumbul Ahmad Desai, Apple's vice president of health. Apple had been interested for years in trying to identify high blood pressure, she told Reuters. The condition affects more than 1 billion people globally, but half of the adults with it go undiagnosed, in part because the standard for measuring blood pressure - a cuff called a sphygmomanometer - is something many people encounter only at a doctor's office. Apple used AI to sort through the data from 100,000 people enrolled in a heart and movement study it originally launched in 2019 to see whether it could find features in the signal data from the watch's main heart-related sensor that it could then match up with traditional blood pressure measurements, Desai said. After multiple layers of machine learning, Apple came up with an algorithm that it then validated with a specific study...